Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
To elucidate the effects of IL-4Rα blockade on the cellular level, we used flow cytometry to examine cytokine production after antigen stimulation in human T cells from patients with AD (n = 12) and healthy controls (n = 6).
|
31596502 |
2020 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab (monoclonal antibody against interleukin-4 receptor α) is approved for the treatment of adolescents with moderate-to-severe AD who are inadequately responsive to standard of care (U.S.A.) or candidates for systemic therapy (European Union).
|
31595499 |
2020 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that clinical improvement of AD that is mediated by interleukin-4 receptor α inhibition and the subsequent suppression of type 2 inflammation is correlated with increased microbial diversity and reduced abundance of S. aureus.
|
31252032 |
2020 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab targets IL-4Rα and is used for moderate-to-severe atopic dermatitis (AD).
|
31737955 |
2020 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinical trial data for dupilumab, a monoclonal antibody against the interleukin-4 receptor (IL-4Rα), have shown that it is safe and effective for the treatment of moderate to severe atopic dermatitis in patients whose disease is resistant to other therapies.
|
31286499 |
2020 |
Eczema
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biologics targeting IL-13, such as the anti-IL-4Rα antibody dupilumab and the anti-IL-13 antibody tralokinumab, successfully improve AD lesions and further highlight the importance of IL-13 in the pathogenesis of AD.
|
31509236 |
2019 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor α (IL-4Rα) subunit, demonstrated efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma).
|
30488542 |
2019 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody that binds to the α subunit of the IL-4 receptor (IL-4Rα) and has been approved for the treatment of adults with severe atopic dermatitis, has been shown in recent phase 3 trials to also have significant clinical benefits in the asthmatic population irrespective of baseline eosinophil counts.
|
30407206 |
2019 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
In March 2017, dupilumab, a human anti-IL-4Rα antibody, became the first biologic to receive approval in the United States for the treatment of moderate-to-severe AD.
|
30825336 |
2019 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (T<sub>H</sub>2)-mediated allergic diseases such as asthma and atopic dermatitis.
|
31123339 |
2019 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody that binds IL-4Rα and inhibits signaling of both IL-4 and IL-13, has shown efficacy across multiple diseases with underlying type 2 signatures and is approved for treatment of asthma, atopic dermatitis and chronic sinusitis with nasal polyposis.
|
31838750 |
2019 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis.
|
31603635 |
2019 |
Eczema
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rare coding variants associated with AD are further enriched in 5 genes (IL-4 receptor [IL4R], IL13, Janus kinase 1 [JAK1], JAK2, and tyrosine kinase 2 [TYK2]) of the IL13 pathway, all of which are targets for novel systemic AD therapeutics.
|
31707051 |
2019 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Following the ability of dupilumab has proved its ability to act on the interleukin 4 receptor in treating atopic dermatitis.
|
29248519 |
2018 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human mAb targeting the IL-4 Rα subunit, blocks signaling of both IL-4 and IL-13 and is the first biologic to be approved for the treatment of moderate-to-severe AD in adult patients.
|
29122151 |
2018 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a fully human monoclonal antibody against the interleukin-4-receptor α subunit, has been developed and used in clinical trials to treat atopic dermatitis (AD).
|
29472119 |
2018 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab, a monoclonal antibody against interleukin-4 receptor alpha, is a promising new treatment option for atopic dermatitis.
|
29312544 |
2017 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab: human monoclonal antibody against IL-4Rα for moderate to severe atopic dermatitis.
|
29238761 |
2017 |
Eczema
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis.
|
28478972 |
2017 |
Eczema
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We observed an association of rs1805011 polymorphism of IL4Rα gene with allergy (p=0.021), mild asthma (p=0.00005) and atopic dermatitis (p=0.0056).
|
26426602 |
2016 |
Eczema
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was a significant (P < 0.01) association between genotype and allele frequencies of IL-4Rα (A+4679G) (I50V) polymorphism in the AD group (but not non-AD group).
|
27018548 |
2016 |
Eczema
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In Egyptian children, the IL-4Rα and the STAT6 polymorphism may play a role in susceptibility to AD.
|
24742632 |
2014 |
Eczema
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the role of polymorphisms in IL-4RA gene in conferring susceptibility to the development of AD and/or JCP using a family analysis and an association analysis in a Japanese population.
|
21918367 |
2012 |
Eczema
|
0.400 |
Biomarker
|
disease |
CTD_mouse |
Genetic and environmental risk factors for childhood eczema development and allergic sensitization in the CCAAPS cohort.
|
19759553 |
2010 |